glp 1 agonist cardiovascular outcomes Cardiovascular, mortality, and kidney with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Cardiovascular outcome studies with GLP-1

We further explore the potential actions of multi-agonist drugs as well as the mechanisms through which gut-brain communication can be used to achieve long-term weight loss without negative side effects

22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.

However, the causal relationship between GLP-1RAs and psychiatric and neurodevelopmental conditions remains unclear

Learn about the benefits and savings opportunities of the SmithRx Weight Management Pathway.

This study aims to comprehensively review the impact of GLP-1 RAs on various body systems, emphasizing both positive and negative effects while addressing existing knowledge gaps in the literature